FDA Finds Bugs and Mold at Chinese Factories Supplying Weight-Loss Drug Ingredients

Food and Drug Administration (FDA) inspectors have identified significant contamination issues, including the presence of insects and mold, at two Chinese factories that produce components for popular GLP-1 weight-loss drugs. The findings have resulted in the facilities being placed on the FDA's import list, potentially halting their products at U.S. borders.

During inspections, authorities found bugs in the ceiling and moldy floors at a facility operated by Chengdu Shengnuo Biopharm Co. According to documents obtained under a Freedom of Information Act request, FDA inspectors observed employees attempting to dispose of product samples by pouring them into sinks, describing it as a "seemingly coordinated effort." Employees were also seen hastily moving documents, which inspectors were unable to fully recover.

At a second factory, Nanjing Chengong Pharmaceutical Co., staff were reportedly acquiring active ingredients from other manufacturers and applying their own company's seal of approval without verifying the associated testing and safety documentation.

These facilities were producing semaglutide and tirzepatide, the active ingredients in widely used weight-loss medications manufactured by pharmaceutical companies like Novo Nordisk and Eli Lilly. The compounding pharmacies involved were reportedly creating black-market versions of these drugs, which have not been approved by safety regulators.

While the actual finished drugs were not tested by the FDA during these inspections, the contamination of the raw ingredients raises concerns about product safety. Chengdu Shengnuo Biopharm Co. has stated in a filing with China's government that it is implementing corrective measures. Both companies have been added to the FDA's import alert list.

Compounded drugs, particularly those involving peptides, represent a significant market. Concerns about the safety of unregulated peptides persist, with little known about their long-term effects. The FDA is evaluating the possibility of allowing overseas compounding pharmacies to produce various types of peptides, with some operating under the belief that U.S. law permits the sale of generic alternatives.

This situation evokes the 2012 fungal meningitis outbreak linked to contaminated steroid injections from the New England Compounding Pharmacy, which resulted in 64 deaths and over 700 infections. The current administration, through Health Secretary Robert F. Kennedy, has previously expressed support for easing restrictions on peptides. Neither the implicated Chinese labs nor the FDA immediately responded to requests for comment on the latest findings.